GHK-Cu: A Copper Carrier for the Repair Scaffold

The short version

GHK-Cu is a very small peptide — three amino acids (glycine, histidine, lysine) — bound to a single copper ion. You will also see it called copper tripeptide-1 or Copper Tripeptide GHK-Cu. The same GHK sequence occurs naturally inside type I collagen, the main structural protein of skin and tendon, which is a clue to what it does: at low concentrations it signals skin and connective-tissue cells to rebuild their scaffolding of collagen and elastin ^[16].

Of the six compounds here, GHK-Cu has the most human evidence — but that evidence is mostly topical, applied to the surface of the skin, and it comes with a built-in constraint: the peptide does not cross intact skin easily on its own ^[13]. Topical copper-peptide products are legal and widely available as cosmetics; injectable or systemic use is unapproved and research-only. This page summarizes the studies and lists no dose or regimen.

What it is

GHK-Cu is the linear tripeptide glycyl-L-histidyl-L-lysine, chelated (that is, held in a stable claw-like grip) one-to-one to a copper(II) ion. The copper is coordinated through the histidine ring, the glycine amino group, and a backbone nitrogen, leaving the lysine side chain free. The complex carries a small positive charge. The bare GHK sequence appears endogenously within the alpha-2(I) chain of type I collagen and in the matrix protein SPARC/osteonectin — the body already uses this motif, and the copper is required for most of its reported biological activity ^[16].

How it works

GHK-Cu plays two overlapping roles: it is a copper chaperone (a carrier that delivers copper to where it is needed for enzymatic reactions) and a broad-spectrum signaling molecule. At picomolar-to-nanomolar concentrations it directly tells dermal fibroblasts — the skin's matrix-making cells — to synthesize collagen, elastin, glycosaminoglycans and the proteoglycan decorin, while rebalancing the enzymes that break matrix down (matrix metalloproteinases) against their natural inhibitors ^[16]. The copper itself enables lysyl-oxidase-mediated cross-linking that knits collagen and elastin into proper fibers, plus a superoxide-dismutase-like antioxidant activity.

At the gene level, a Connectivity Map analysis reported that GHK shifts expression of roughly 31.2% of human genes at a 50%-or-greater change threshold (about 59% up, 41% down), strongly stimulating protein-quality-control (ubiquitin-proteasome) and DNA-repair gene sets ^[14]. One correction to cite accurately: the often-repeated "~4,000 genes" figure is an extrapolation; the verified 50%-threshold table reports on the order of 2,100 genes ^[14].

What the research shows

Skin regeneration. The canonical skin review documents GHK-Cu stimulating synthesis of collagen, dermatan sulfate, chondroitin sulfate and decorin, notes that plasma GHK falls from about 200 ng/mL at age 20 to about 80 ng/mL by age 60, and reports that topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid ^[16].

Gene expression. The 2018 analysis quantified the broad transcriptomic shift toward tissue-repair, protein-quality-control, DNA-fidelity and antioxidant programs ^[14].

A controlled human signal. In a 6-month trial of 45 men with male-pattern hair loss, a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide increased hair count by 52.6 at 100 mg/mL and 71.5 at 50 mg/mL versus 9.6 for placebo, with no adverse events in any group ^[15]. This is a combination product, not pure GHK-Cu, but it is the strongest placebo-controlled human efficacy signal for a GHK-containing topical.

The delivery challenge. A 2025 review confirms poor skin permeability is the central formulation problem, and evaluates strategies including palmitoylation and microneedle pretreatment (~134 nmol GHK permeated with microneedling versus none through intact skin) ^[13]. A separate ex-vivo skin-penetration study quantified a measurable dermal copper depot forming over 48 hours from topical GHK-Cu application ^[17].

Reported effects, cautions & safety

Topical copper-peptide products carry a long real-world safety record, but several cautions are documented in the literature:

• No approved drug indication. There is no FDA- or EMA-approved therapeutic GHK-Cu product by any route. Topical copper tripeptide-1 is a legal cosmetic ingredient; injectable or systemic use is unapproved and research-only ^[13].
• Thin evidence beyond skin. Human clinical data are limited to small topical dermatology trials and the single 45-patient combination hair-loss study. There is no validated human pharmacokinetic data for injectable or systemic GHK-Cu ^[15].
• Localized pigmentation. Localized hyperpigmentation has been reported with some topical copper-peptide applications — roughly 40% in one acne-scar microneedling study.
• Formulation incompatibility. Vitamin C and low-pH acids can reduce the copper ion and destroy both actives — a user-error risk in layered skincare.
• Theoretical copper accumulation. Prolonged systemic use raises a theoretical copper-balance question, though no human copper-toxicity cases attributed to GHK-Cu appear in the peer-reviewed record.
• Single-investigator origin. A large share of foundational mechanistic and review literature comes from one investigator and colleagues, limiting independent replication of the broader anti-aging and gene-expression claims ^[14].

No community-anecdote reports are compiled for GHK-Cu as a standalone compound in this site's source material.

Where it fits in recovery research

GHK-Cu is the matrix-and-skin specialist of the group, and the one with the strongest human footing — but that footing is mostly on the skin surface, where its own delivery problem limits how far the benefit reaches ^[13]. Where BPC-157 and TB-500 live almost entirely in animal models, GHK-Cu has decades of topical cosmetic use behind it; what it lacks is validated systemic human data. It also forms the mass-dominant component of the KLOW blend. Compare all six on the compare page.